|
시장보고서
상품코드
1877406
세계의 안면 홍반 치료 시장 : 약제 유형별, 제품 유형별, 질환 유형별, 유통 채널별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 규모, 점유율 및 예측(2025-2032년)Facial Erythema Treatment Market, By Drug Type, By Product Type, By Disease Type, By Distribution Channel, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032 |
||||||
안면 홍반 치료 시장 규모는 2024년 1억 9,800만 달러로 평가되었으며, 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 5.6%를 나타낼 전망입니다.
안면 홍반 치료는 주사, 광선 과민증, 혈관 확장 및 염증성 피부 질환으로 인한 만성 또는 발작성 안면 홍조를 조절하는 것을 목표로하는 다양한 치료 접근법으로 구성됩니다. 이 시장에는 처방전 외용제, 장치 기반 치료법, 경구 항염증제, 눈에 보이는 붉은 색을 줄이고 피부 장벽을 강화하는 것을 목표로 한 고급 피부과 치료가 포함됩니다. 세계적인 술의 발병률 상승과 미용 피부 젊어짐에 대한 수요 증가는 시장 성장을 견인하고 있으며, 특히 비침습적인 미용 솔루션을 요구하는 젊은 층에서 두드러집니다. 혈관 표적화를 개선한 차세대 외용제뿐만 아니라 냉각·혈관조절·LED 요법을 조합한 다기능 디바이스는 큰 비즈니스 기회를 제시하고 있습니다. AI 진단기술과 성분혁신에 뒷받침된 「개인화된 피부과학」으로의 이행이 현저한 동향입니다. 그러나, 치료의 변동, 고액의 시술 비용, 장기적인 해결책의 부족이, 비용 중시 시장에서의 보급의 장벽이 되고 있습니다.
안면 홍반 치료 시장 역학
피부 건강에 대한 일반 인식 증가는 시장 성장을 가속
피부 건강 및 안면 홍반의 미용적 영향에 대한 일반적인 인식 증가는 안면 홍반 치료 시장의 주요 성장 촉진요인입니다. 계발 캠페인, 소셜 미디어를 활용한 정보 발신, 피부과학 분야의 대처에 의해 술(로자세아)등의 질환에 대한 환자의 이해가 깊어져, 조기 진단과 치료 준수율의 향상으로 이어지고 있습니다. 전미 술 협회(National Rosacea Society)에 의하면, 계발 활동에 의해 지난 5년간 미국에서의 술의 진단 건수는 25% 증가하고, 의료 치료를 요구하는 환자수가 증가하고 있습니다. 이 추세를 뒷받침하는 것처럼 가르델마는 2024년 3월 안면홍반에 대한 선진적인 외용제를 출시하여 4주 이내에 붉은 색을 40% 완화하는 효과를 실현했습니다. 이 출시는 증가 인지도와 혁신적인 치료법의 조합이 환자 수요와 시장 확대를 촉진하고 있음을 보여줍니다.
안면 홍반 치료 시장 : 세분화 분석
세계 시장은 약물 유형, 제품 유형, 질병 유형, 유통 채널, 최종 사용자 및 지역에 따라 세분화됩니다.
약물 유형별로 항생제는 안면 홍반 치료 시장의 주요 수익원 부문입니다. 이는 지속적인 안면 홍반을 일으킬 수 있는 술(로자세아)과 같은 염증성 피부 질환 치료에서 입증된 효능 때문입니다. 독시사이클린과 미노사이클린은 효과적인 항균·항염증제이며 임상 현장에서 널리 사용되고 있습니다. 2023년 시장 조사에 따르면 항생제 클래스는 전 세계적으로 약 6억 1,750만 달러의 수익을 창출했습니다. 2024년 11월, 저니 메디컬 코퍼레이션이 술(병변과 적색 포함)에 대한 항생제 기반 경구 치료제 '엠로시(Emrosi : DFD-29)'의 FDA 승인을 받았습니다. 이것은이 범주에서 항생제 치료의 중요한 진전을 보여줍니다.
제품 유형별로는 브리모니딘이나 메트로니다졸 등의 처방전·시판약 크림의 보급에 의해 외용 치료제 부문이 안면 홍반 치료 시장에서 큰 점유율을 차지하고 있습니다. 이러한 치료법은 편의성이 높고 비용 효과적이며 안면 적색을 효과적으로 줄이기 때문에 많은 환자의 치료에 있어서 의사의 우선 선택이 되고 있습니다. 의사의 지속적인 권고와 비침습적 치료법에 대한 소비자 기호의 고조가 함께 선진국·신흥국 시장 양쪽에서 지속적인 채용과 수익 창출을 지지하고 있습니다. 예를 들어, 가르델마는 2025년(2024년 실적보고)에서 환율 변동의 영향을 제외한 기준으로 전년대비 9.3% 증가한 44억 1,000만 달러의 순매출을 보고했습니다. 이 회사의 피부과 스킨케어 카테고리(외용술 치료제 포함)는 2024년 10.7% 성장을 기록했습니다.
안면 홍반 치료 시장 - 지역별 분석
북미에서는 다른 지역보다 시장 성장을 가속하는 여러 요인이 있습니다. 주요 요인으로는 의약품 및 의료기기에 대한 정부의 높은 연간 건강 관리 지출과 사회적인지도가 있습니다. 미국 로사시아 협회(NRS)는 2018년 약 1,600만 명의 미국인이 로사시아로 고통받았습니다. 이러한 동향에 의해 안면 홍반에 고민하는 환자가 진료소나 병원을 진찰하는 케이스가 증가해, 해당 지역 시장 규모 확대가 기대됩니다. 또한, 많은 국제 기업들이 주요 병원 체인과 제휴하고 있는 것도, 이 지역 시장을 지지하는 요인이 되어, 조사 대상 시장의 사업을 촉진하고 있습니다.
미국의 안면 홍반 치료 시장 - 국가별 분석
미국은 술의 이환율 증가, 확립된 피부과 의료 인프라, 처방전 치료 및 미용 치료에 대한 환자의 높은 수용성으로 인해 북미 안면 홍반 치료 시장에서 주요 수익 창출국입니다. 미국 술 협회에 따르면, 술은 1,600만 명의 미국인에게 영향을 미치고 있으며, 외용 혈관 수축제, 레이저 치료, 항염증제에 대한 안정적인 수요를 창출하고 있습니다. 피부과 클리닉에서 고급 레이저 장치의 사용 확대가 시장을 뒷받침하고 있습니다.
안면 홍반 치료 시장 : 경쟁 구도
안면 홍반 치료 시장은 중등도의 경쟁환경으로 여러 제약회사 및 피부과 관련 기업들이 외용요법, 레이저장치, 복합치료 옵션의 혁신을 추진하고 있습니다. Galderma, Allergan Aesthetics (AbbVie), Leo Pharma, Bausch Health, Candela Corporation 등이 주요 기업로서 시장에서의 지위 강화를 위한 제품 개발과 임상적 진보에 많은 투자를 하고 있습니다. 각사는 치료효과 향상, 부작용 경감, 술 관련 홍반 등의 증상에 대한 즉각적인 제제 개발을 통해 경쟁을 전개하고 있습니다. 예를 들어, 2023년 5월에는 가르델마사가 Epsolay(R)(과산화벤조일 5% 크림)의 양호한 임상 데이터를 발표하고, Rhofade(R)(옥시메타졸린 1% 크림)의 신규 시장으로의 지속적인 확대에 의해 안면 홍조 관리 분야에서의 리더십을 강화했습니다. 시장 경쟁은 지속적인 R&D 투자, 제품 적응증 확대, 피부과 클리닉 및 미용 센터와의 전략적 제휴에 의해 형성됩니다.
목차
제1장 안면 홍반 치료 시장 개요
- 분석 범위
- 시장 추정 기간
제2장 주요 요약
- 시장 분석
- 경쟁 인사이트
제3장 안면 홍반 치료의 주요 시장 동향
- 시장 성장 촉진요인
- 시장 성장 억제요인
- 시장 기회
- 시장 전망 동향
제4장 안면 홍반 치료 시장 : 산업 분석
- PEST 분석
- Porter's Five Forces 분석
- 시장 성장 전망 : 매핑
- 규제 체제의 분석
제5장 안면 홍반 치료 시장 : 높아지는 지정학적 긴장의 영향
- COVID-19 팬데믹의 영향
- 러시아·우크라이나 전쟁의 영향
- 중동 분쟁의 영향
제6장 안면 홍반 치료 시장 상황
- 안면 홍반 치료 시장 점유율 분석(2024년)
- 주요 제조업체별 분석 데이터
- 기존 기업의 분석
- 신흥 기업의 분석
제7장 안면 홍반 치료 시장 : 약제 유형별
- 개요
- 부문별 점유율 분석 : 약제 유형별
- 보습제
- 코르티코스테로이드
- 항히스타민제
- 항진균제
- 항생제
- 칼시뉴린 억제제
제8장 안면 홍반 치료 시장 : 제품 유형별
- 개요
- 부문별 점유율 분석 : 제품 유형별
- 국소 치료제
- 레이저 치료
- 경구용 약물
- 기타
제9장 안면 홍반 치료 시장 : 질환 유형별
- 개요
- 부문별 점유율 분석 : 질환 유형별
- 구진농포성(PPR)
- 홍반성모세혈관확장증(ETR)
- 피마투스형
- 안구형
제10장 안면 홍반 치료 시장 : 유통 채널별
- 개요
- 부문별 점유율 분석 : 유통 채널별
- 병원 약국
- 온라인 약국
- 소매 약국
제11장 안면 홍반 치료 시장 : 최종 사용자별
- 개요
- 부문별 점유율 분석 : 최종 사용자별
- 병원
- 재택치료
- 피부과 클리닉
제12장 안면 홍반 치료 시장 : 지역별
- 서론
- 북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
- 유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
- 아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
- 라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
- 중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타
제13장 주요 벤더 분석 : 안면 홍반 치료 업계
- 경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
- 기업 프로파일
- GlaxoSmithKline plc(GSK)
- Sol-Gel Technologies Ltd.
- Cynosure, Inc.
- Mayne Pharma Group Limited
- Astellas Pharma Inc.
- Galderma
- AbbVie Inc.
- Bausch Health Companies Inc.
- Aclaris Therapeutics, Inc
- Merck &Co., Inc.
- Alma Lasers
- Cutera, Inc.
- Candela Corporation
- LEO Pharma A/S
- Novartis International AG
- Bayer AG
- Pfizer Inc.
- Sanofi SA
- SkinCeuticals
- EltaMD
- Others
제14장 AnalystView의 전방위 분석
KTH 25.12.15The Facial Erythema Treatment Market size was valued at US$ 198 Million in 2024, expanding at a CAGR of 5.6% from 2025 to 2032.
Facial erythema treatment consists of a variety of therapeutic approaches aimed at controlling chronic or episodic facial redness caused by rosacea, photosensitivity, vascular dilation, and inflammatory skin disorders. The market includes prescription topicals, device-based therapies, oral anti-inflammatories, and advanced dermatology procedures aimed at reducing visible redness and strengthening the skin barrier. The rising global incidence of rosacea, as well as the growing demand for cosmetic skin rejuvenation, are driving market growth, particularly among younger demographics looking for noninvasive aesthetic solutions. Next-generation topical agents with improved vascular targeting, as well as multifunctional devices combining cooling, vascular modulation, and LED-based therapy, present significant opportunities. A significant trend is the shift toward personalized dermatology, which is aided by AI-driven diagnostics and ingredient innovation. Nonetheless, treatment variability, high procedural costs, and a lack of long-term solutions continue to limit widespread adoption in cost-sensitive markets.
Facial Erythema Treatment Market- Market Dynamics
Rising Public Awareness of Skin Health Propels Market Growth
The growing public awareness of skin health and the cosmetic impact of facial erythema is a major driver of the Facial Erythema Therapeutics Market. Educational campaigns, social media outreach, and dermatology initiatives have improved patient understanding of conditions such as rosacea, resulting in earlier diagnosis and greater treatment adherence. According to the National Rosacea Society, awareness campaigns have contributed to a 25% increase in rosacea diagnoses in the United States over the last five years, increasing the number of patients seeking medical treatment. Supporting this trend, Galderma launched an advanced topical treatment for facial erythema in March 2024, resulting in a 40% reduction in redness within four weeks. This launch demonstrates how rising awareness, combined with innovative therapies, is fueling patient demand and market expansion.
Facial Erythema Treatment Market- Segmentation Analysis:
The worldwide market is segmented on the basis of Drug Type, Product Type, Disease Type, Distribution Channel, End User, and Region.
Based on Drug Type. Antibiotics are a key revenue-generating segment in the Facial Erythema Treatment Market due to their proven effectiveness in treating inflammatory skin disorders like rosacea, which can cause persistent facial redness. Doxycycline and minocycline are effective antimicrobial and anti-inflammatory agents, making them widely used in clinical practice. According to a 2023 market study, the antibiotics class generated around USD 617.50 million globally. In November 2024, Journey Medical Corporation received FDA approval for Emrosi (DFD-29), an antibiotic-based oral therapy for rosacea, including lesions and redness. This marks a significant advancement for antibiotic treatments in this category.
Based on Product Type, the topical treatments segment holds a significant share in the Facial Erythema Treatment Market, owing to the widespread use of prescription and over-the-counter creams like brimonidine and metronidazole. These treatments are convenient, cost-effective, and efficacious in reducing facial redness, making them a preferred choice among physicians for treating most patients. Continued physician recommendations, combined with growing consumer preference for non-invasive therapies, support sustained adoption and revenue generation in both developed and emerging markets. For instance, in 2025 (reporting 2024 figures), Galderma reported net sales of USD 4.41 billion, up 9.3% year-on-year on a constant currency basis, with its Dermatological Skincare category-including topical rosacea treatments-growing 10.7% in 2024
Facial Erythema Treatment Market- Geographical Insights
North America has a number of factors that help this market grow more than other regions. Some factors include the government's high annual healthcare expenditure on pharmaceuticals and medical devices, as well as societal awareness. The National Rosacea Society (NRS) estimates that approximately 16 million Americans will suffer from rosacea in 2018. Such trends are expected to encourage more patients suffering from facial erythema to visit clinics and hospitals, thereby increasing the studied market in the region. The region is also supported by numerous international companies that collaborate with many major hospital chains, which drives business in the studied market.
United States Facial Erythema Treatment Market- Country Insights
The United States is a major revenue-generating country in the North American facial erythema treatment market, owing to a high prevalence of rosacea, a well-established dermatology care infrastructure, and strong patient adoption of prescription and aesthetic therapies. According to the National Rosacea Society, rosacea affects an estimated 16 million Americans, fueling a steady demand for topical vasoconstrictors, laser therapies, and anti-inflammatory medications. The growing use of advanced laser devices in dermatology clinics bolsters the market.
For example, in 2023, Candela Medical announced the U.S. launch of its upgraded Vbeam Prima pulsed-dye laser platform, which reported improved vascular lesion clearance and growing utilization among dermatologists, directly supporting the country's increased demand for erythema-focused treatment solutions.
Facial Erythema Treatment Market- Competitive Landscape:
The facial erythema treatment market is moderately competitive, with several pharmaceutical and dermatology companies driving innovation in topical therapies, laser devices, and combination treatment options. Galderma, Allergan Aesthetics (AbbVie), Leo Pharma, Bausch Health, and Candela Corporation are among the leading players, with each investing heavily in product development and clinical advancements to strengthen their market position. Companies compete by increasing treatment efficacy, lowering side effects, and creating faster-acting formulations for conditions like rosacea-related erythema. For example, in May 2023, Galderma announced positive clinical data for Epsolay(R) (benzoyl peroxide 5% cream) and the continued expansion of Rhofade(R) (oxymetazoline 1% cream) into new markets, bolstering its leadership in facial redness management. Market competition is shaped by ongoing R&D investment, expanded product indications, and strategic partnerships with dermatology clinics and aesthetic centers.
Recent Developments:
In April 2025, The Kesty Redness Scale (KRS) was introduced as a validated tool for objectively assessing facial erythema severity in clinical settings. The KRS, by providing standardized, quantitative evaluations, enables dermatologists to more effectively monitor patient improvement and compare treatment success across various therapies, thereby improving overall rosacea management.
In March 2025, Journey Medical has released Phase 3 trial results for Emrosi (DFD-29), an oral minocycline-containing rosacea treatment. The study found that the treatment was more effective and safer than doxycycline and placebo, and it had a significant impact on facial erythema and inflammation lesions. Emrosi was a possible new standard for rosacea treatment.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL FACIAL ERYTHEMA TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- GlaxoSmithKline plc (GSK)
- Sol-Gel Technologies Ltd.
- Cynosure, Inc.
- Mayne Pharma Group Limited
- Astellas Pharma Inc.
- Galderma
- AbbVie Inc.
- Bausch Health Companies Inc.
- Aclaris Therapeutics, Inc
- Merck & Co., Inc.
- Alma Lasers
- Cutera, Inc.
- Candela Corporation
- LEO Pharma A/S
- Novartis International AG
- Bayer AG
- Pfizer Inc.
- Sanofi S.A
- SkinCeuticals
- EltaMD
- Others
GLOBAL FACIAL ERYTHEMA TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032
- Emollients
- Corticosteroids
- Antihistamines
- Antifungal
- Antibiotics
- Calcineurin Inhibitors
GLOBAL FACIAL ERYTHEMA TREATMENT MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032
- Topical Treatments
- Laser Therapies
- Oral Medications
- Others
GLOBAL FACIAL ERYTHEMA TREATMENT MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032
- Papulopustular (PPR)
- Erythematotelangiectatic (ETR)
- Phymatous
- Ocular
GLOBAL FACIAL ERYTHEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
GLOBAL FACIAL ERYTHEMA TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals
- Homecare
- Dermatology Clinics
GLOBAL FACIAL ERYTHEMA TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Table of Contents
1. Facial Erythema Treatment Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Facial Erythema Treatment Market Snippet by Drug Type
- 2.1.2. Facial Erythema Treatment Market Snippet by Product Type
- 2.1.3. Facial Erythema Treatment Market Snippet by Disease Type
- 2.1.4. Facial Erythema Treatment Market Snippet by Distribution Channel
- 2.1.5. Facial Erythema Treatment Market Snippet by End User
- 2.1.6. Facial Erythema Treatment Market Snippet by Country
- 2.1.7. Facial Erythema Treatment Market Snippet by Region
- 2.2. Competitive Insights
3. Facial Erythema Treatment Key Market Trends
- 3.1. Facial Erythema Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Facial Erythema Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Facial Erythema Treatment Market Opportunities
- 3.4. Facial Erythema Treatment Market Future Trends
4. Facial Erythema Treatment Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Facial Erythema Treatment Market: Impact of Escalating Geopolitical Tensions
- 5.1. Impact of COVID-19 Pandemic
- 5.2. Impact of Russia-Ukraine War
- 5.3. Impact of Middle East Conflicts
6. Facial Erythema Treatment Market Landscape
- 6.1. Facial Erythema Treatment Market Share Analysis, 2024
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Facial Erythema Treatment Market - By Drug Type
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2024 & 2032 (%)
- 7.1.2. Emollients
- 7.1.3. Corticosteroids
- 7.1.4. Antihistamines
- 7.1.5. Antifungal
- 7.1.6. Antibiotics
- 7.1.7. Calcineurin Inhibitors
8. Facial Erythema Treatment Market - By Product Type
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
- 8.1.2. Topical Treatments
- 8.1.3. Laser Therapies
- 8.1.4. Oral Medications
- 8.1.5. Others
9. Facial Erythema Treatment Market - By Disease Type
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Disease Type, 2024 & 2032 (%)
- 9.1.2. Papulopustular (PPR)
- 9.1.3. Erythematotelangiectatic (ETR)
- 9.1.4. Phymatous
- 9.1.5. Ocular
10. Facial Erythema Treatment Market - By Distribution Channel
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
- 10.1.2. Hospital Pharmacies
- 10.1.3. Online Pharmacies
- 10.1.4. Retail Pharmacies
11. Facial Erythema Treatment Market - By End User
- 11.1. Overview
- 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
- 11.1.2. Hospitals
- 11.1.3. Homecare
- 11.1.4. Dermatology Clinics
12. Facial Erythema Treatment Market- By Geography
- 12.1. Introduction
- 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
- 12.2. North America
- 12.2.1. Overview
- 12.2.2. Facial Erythema Treatment Key Manufacturers in North America
- 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.2.5. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.2.6. North America Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.9. U.S.
- 12.2.9.1. Overview
- 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.9.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.2.9.4. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.2.9.5. U.S. Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.2.10. Canada
- 12.2.10.1. Overview
- 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.2.10.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.2.10.4. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.2.10.5. Canada Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3. Europe
- 12.3.1. Overview
- 12.3.2. Facial Erythema Treatment Key Manufacturers in Europe
- 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.5. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.6. Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.9. Germany
- 12.3.9.1. Overview
- 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.9.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.9.4. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.9.5. Germany Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.10. UK
- 12.3.10.1. Overview
- 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.10.3. UK Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.10.4. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.10.5. UK Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.11. France
- 12.3.11.1. Overview
- 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.11.4. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.11.5. France Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.12. Italy
- 12.3.12.1. Overview
- 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.12.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.12.4. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.12.5. Italy Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.13. Spain
- 12.3.13.1. Overview
- 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.13.3. Spain Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.13.4. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.13.5. Spain Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.14. The Netherlands
- 12.3.14.1. Overview
- 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.14.3. The Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.14.4. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.14.5. The Netherlands Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.15. Sweden
- 12.3.15.1. Overview
- 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.15.4. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.15.5. Sweden Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.16. Russia
- 12.3.16.1. Overview
- 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.16.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.16.4. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.16.5. Russia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.17. Poland
- 12.3.17.1. Overview
- 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.17.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.17.4. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.17.5. Poland Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.3.18. Rest of Europe
- 12.3.18.1. Overview
- 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.3.18.4. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.3.18.5. Rest of the Europe Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4. Asia Pacific (APAC)
- 12.4.1. Overview
- 12.4.2. Facial Erythema Treatment Key Manufacturers in Asia Pacific
- 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.4.4. APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.5. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.6. APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.9. China
- 12.4.9.1. Overview
- 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.9.4. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.9.5. China Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.10. India
- 12.4.10.1. Overview
- 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.10.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.10.4. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.10.5. India Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.11. Japan
- 12.4.11.1. Overview
- 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.11.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.11.4. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.11.5. Japan Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.12. South Korea
- 12.4.12.1. Overview
- 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.12.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.12.4. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.12.5. South Korea Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.13. Australia
- 12.4.13.1. Overview
- 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.13.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.13.4. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.13.5. Australia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.14. Indonesia
- 12.4.14.1. Overview
- 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.14.4. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.14.5. Indonesia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.15. Thailand
- 12.4.15.1. Overview
- 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.15.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.15.4. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.15.5. Thailand Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.16. Philippines
- 12.4.16.1. Overview
- 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.16.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.16.4. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.16.5. Philippines Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.4.17. Rest of APAC
- 12.4.17.1. Overview
- 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.4.17.4. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.4.17.5. Rest of APAC Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5. Latin America (LATAM)
- 12.5.1. Overview
- 12.5.2. Facial Erythema Treatment Key Manufacturers in Latin America
- 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.5.4. LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.5. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.5.6. LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.9. Brazil
- 12.5.9.1. Overview
- 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.9.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.9.4. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.5.9.5. Brazil Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.10. Mexico
- 12.5.10.1. Overview
- 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.10.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.10.4. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.5.10.5. Mexico Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.11. Argentina
- 12.5.11.1. Overview
- 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.11.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.11.4. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.5.11.5. Argentina Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.12. Colombia
- 12.5.12.1. Overview
- 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.12.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.12.4. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.5.12.5. Colombia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.5.13. Rest of LATAM
- 12.5.13.1. Overview
- 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.5.13.4. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.5.13.5. Rest of LATAM Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6. Middle East and Africa
- 12.6.1. Overview
- 12.6.2. Facial Erythema Treatment Key Manufacturers in Middle East and Africa
- 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.5. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.6. Middle East and Africa Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.9. Saudi Arabia
- 12.6.9.1. Overview
- 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.9.4. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.9.5. Saudi Arabia Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.10. United Arab Emirates
- 12.6.10.1. Overview
- 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.10.4. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.10.5. United Arab Emirates Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.11. Israel
- 12.6.11.1. Overview
- 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.11.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.11.4. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.11.5. Israel Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.12. Turkey
- 12.6.12.1. Overview
- 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.12.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.12.4. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.12.5. Turkey Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.13. Algeria
- 12.6.13.1. Overview
- 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.13.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.13.4. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.13.5. Algeria Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.14. Egypt
- 12.6.14.1. Overview
- 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.14.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.14.4. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.14.5. Egypt Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 12.6.15. Rest of MEA
- 12.6.15.1. Overview
- 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 12.6.15.4. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 12.6.15.5. Rest of MEA Market Size and Forecast, By Disease Type, 2019 - 2032 (US$ Million)
- 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Facial Erythema Treatment Industry
- 13.1. Competitive Benchmarking
- 13.1.1. Competitive Dashboard
- 13.1.2. Competitive Positioning
- 13.2. Company Profiles
- 13.2.1. GlaxoSmithKline plc (GSK)
- 13.2.2. Sol-Gel Technologies Ltd.
- 13.2.3. Cynosure, Inc.
- 13.2.4. Mayne Pharma Group Limited
- 13.2.5. Astellas Pharma Inc.
- 13.2.6. Galderma
- 13.2.7. AbbVie Inc.
- 13.2.8. Bausch Health Companies Inc.
- 13.2.9. Aclaris Therapeutics, Inc
- 13.2.10. Merck & Co., Inc.
- 13.2.11. Alma Lasers
- 13.2.12. Cutera, Inc.
- 13.2.13. Candela Corporation
- 13.2.14. LEO Pharma A/S
- 13.2.15. Novartis International AG
- 13.2.16. Bayer AG
- 13.2.17. Pfizer Inc.
- 13.2.18. Sanofi S.A
- 13.2.19. SkinCeuticals
- 13.2.20. EltaMD
- 13.2.21. Others
14. 360 Degree Analyst View
15. Appendix
- 15.1. Research Methodology
- 15.2. References
- 15.3. Abbreviations
- 15.4. Disclaimer
- 15.5. Contact Us
